Bristol Myers Squibb (NYSE:BMY) will commence a tender offer to acquire all outstanding shares of 2seventy bio at a price of $5.00 a share.The deal represents an 88% premium to the closing price ...

CAMBRIDGE, Mass., March 11, 2025--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb ...

Bristol Myers Squibb is acquiring 2seventy bio, a deal that gives the pharmaceutical giant full control over the partnered ...

Bristol Myers Squibb (BMS) plans to buy out its partner in developing the blockbuster multiple myeloma drug Abecma ® (idecabtagene vicleucel), by agreeing to acquire 2seventy bio for ...

Bristol Myers Squibb has moved to take full control of the CAR-T therapy it partners with 2seventy bio, agreeing to buy the biotech for around $286 million. The $5.00-per-share offer – announced ...

May 07, 2025--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq ... anticipated closing of the acquisition of 2seventy by Bristol Myers Squibb (BMS) this quarter, we will continue to deliver Abecma ...

March 11 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab will acquire 2seventy bio (TSVT.O), opens new tab for about $286 million in cash, sending the cancer cell therapy maker's shares up ...

2seventy bio, Inc., a pharmaceutical company based in Cambridge, Massachusetts, has successfully completed a merger agreement with Bristol-Myers Squibb Company (NYSE:BMY). According to InvestingPro ...

Bristol Myers Squibb (BMS) plans to invest $40bn in the US over the next five years to bolster its research and manufacturing ...

2seventy bio (NASDAQ:TSVT) shares popped nearly 4% premarket on Tuesday after it entered a deal to be acquired by Bristol Myers Squibb (NYSE:BMY) in an ~$286M all-cash transaction (or $102M net of ...

2seventy bio, Inc., a pharmaceutical company based in Cambridge, Massachusetts, has successfully completed a merger agreement with Bristol-Myers Squibb Company (NYSE:BMY). According to ...